Assembly Biosciences (NASDAQ:ASMB) Releases Quarterly Earnings Results, Beats Expectations By $0.18 EPS

Assembly Biosciences (NASDAQ:ASMB) posted its earnings results on Thursday. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.75) by $0.18, Zacks reports. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%. The company had revenue of $7.36 million for the quarter, compared to analysts’ expectations of $7.05 million.

Assembly Biosciences Price Performance

ASMB stock opened at $11.01 on Friday. Assembly Biosciences has a 1 year low of $10.27 and a 1 year high of $19.93. The company has a market cap of $69.98 million, a P/E ratio of -1.64 and a beta of 0.62. The firm has a 50-day moving average of $12.91 and a 200 day moving average of $15.15.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “neutral” rating on shares of Assembly Biosciences in a research note on Friday, December 27th.

Insider Buying and Selling

In other Assembly Biosciences news, Director Michael Houghton acquired 3,202 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average price of $15.61 per share, with a total value of $49,983.22. Following the completion of the purchase, the director now directly owns 3,202 shares of the company’s stock, valued at approximately $49,983.22. The trade was a ? increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.10% of the stock is currently owned by insiders.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.